News >

FDA Expands Optune's Glioblastoma Multiforme Indication

Silas Inman @silasinman
Published: Monday, Oct 05, 2015

William Maisel, MD

William Maisel, MD, MPH

The FDA has approved Optune (formally the NovoTTF-100A System) in combination with adjuvant temozolomide as a treatment for patients with newly diagnosed glioblastoma multiforme (GBM) following surgery, chemotherapy, and radiation therapy, based on an improvement in survival in the EF-14 trial.

“These results are spectacular,” lead investigator Roger Stupp, MD, director of the University Hospital Cancer Center at the University of Zurich, Zurich, Switzerland, said in a statement when the findings were presented. “A new standard of care for patients suffering from glioblastoma is born.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication